Effects of D-Nebivolol and L-Nebivolol on Left Ventricular Systolic and Diastolic Function

Stoleru, L.; Wijns, William; Eyll, Christian van; Bouvy, T.; Nueten, Luc Van; Pouleur, H.

doi:10.1097/00005344-199308000-00002

Cited by 56 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In vitro studies have shown that nebivolol dilates coronary resistance vessels in humans through an agonist effect on endothelial b3-adrenoreceptors to release nitric oxide and promote neoangiogenesis [19]. The nitric oxide-releasing and vasodilating properties of nebivolol in coronary microvessels may exert its beneficial effect in patients with ischemic and dilated cardiomyopathies [20], particularly those with diastolic dysfunction [21], given the direct lusitropic properties of nitric oxide on the myocardium. Diseases such as dyslipidemia, diabetes, and atherosclerosis are all associated with a decrease in eNOS expression, nitric oxide bioavailability, or both, which could limit the clinical impact of a drug that depends on nitric oxide release.…”

Section: Discussionmentioning

confidence: 99%

Does the β-Blocker Nebivolol Increase Coronary Flow Reserve?

Togni

Vigorito

Windecker

et al. 2007

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Does the β-Blocker Nebivolol Increase Coronary Flow Reserve?

Togni

Vigorito

Windecker

et al. 2007

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

show abstract

“…[13][14][15][16][17] This worthy positive experience was of enhanced wellbeing, reported by 47 patients (15 nebivolol, 12 atenaspect has considerable potential. Many patients with hypertension have concomitant coronary artery olol, 20 placebo).…”

Section: Methodsmentioning

confidence: 99%

Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial

Nueten

Taylor²,

Robertson

1998

J Hum Hypertens

View full text Add to dashboard Cite

A double-blind, randomised, parallel-group trial was cant falls in heart rate. Both active drugs were well tolerconducted in patients with essential hypertension in ated, nebivolol marginally more so. Nebivolol, a longBritish general practices, of nebivolol 5 mg, atenolol acting, cardioselective, vasodilating beta-blocker which 50 mg, and placebo each given once daily. Both active acts partly via the l-arginine/nitric oxide mechanism, drugs, in comparison with placebo, caused highly sigappears potentially valuable for the treatment of hypernificant and similar reductions in systolic and diastolic tension. pressures without orthostatic effect, and small signifiKeywords: nitric oxide; quality of life; side effects daily were begun. After 4 weeks of this single-blind

show abstract

“…Such vasodilatation may contribute to the favourable effects on exercise nulated arm. During coinfusion of the highest dose of nebivolol with l-NMMA, mean blood flow was tolerance and quality of life of nebivolol in comparison with atenolol [15,16] and explain the finding that it 2.94±0.42 ml min −1 100 ml forearm −1 ( P<0.0006 for the comparison of infusion of l-NMMA vs saline with improves the left ventricular function of patients with hypertension [17]. NO has several potential antiatherognebivolol), similar to blood flow in the noncannulated arm which was 2.98±0.33 ml min −1 100 ml −1 forearm.…”

mentioning

confidence: 99%

The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension

Dawes

Brett

Chowienczyk

et al. 1999

Brit J Clinical Pharma

114

View full text Add to dashboard Cite

Aims Brachial artery administration of nebivolol increases forearm blood flow in normotensive subjects through activation of the l-arginine/NO pathway. The aim of the present study was to investigate the effect of brachial artery administration of nebivolol in subjects with essential hypertension. Methods We studied eight patients with uncomplicated essential hypertension and serum cholesterol less than 6.9 mmol l −1 . Antihypertensive medication was discontinued 2 weeks before the study in previously treated patients. Following cannulation of the left brachial artery, saline was infused to establish baseline blood flow, followed by increasing doses of nebivolol (88.5, 177 and 354 mg min −1 , each dose for 6 min), followed by saline for 12 min, followed by a 30 min infusion of l-NMMA (2 mg min −1 ). During the final 18 min of the l-NMMA infusion, nebivolol was coinfused using the same doses as before. Forearm blood flow was measured in both arms using venous occlusion plethysmography. Results Blood flow in the noninfused arm did not change significantly throughout the study. In the infused arm blood flow increased significantly in a dose-related manner during the first series of nebivolol infusions from 2.76±0.39 ml min −1-1 100 ml forearm −1 during the baseline period to 4.40±0.60 ml min −1-1 100 ml forearm −1 (mean±s.e. mean, n=8, P=0.0003 by anova). l-NMMA antagonized the vasodilator effect of nebivolol: baseline blood flow in the infused arm was 2.41±0.53 ml min −1 100 ml forearm −1 and 2.94±0.42 ml min −1 100 ml forearm −1 during coinfusion of the top dose of nebivolol with l-NMMA ( P= 0.0006 for an effect of l-NMMA on nebivolol response). There were no serious adverse events. Conclusions Nebivolol causes vasodilation in the forearm vascular bed in subjects with essential hypertension. Since this response is antagonized by l-NMMA, the vasodilatation is probably caused by activation of the l-arg/NO pathway.

show abstract

Effects of D-Nebivolol and L-Nebivolol on Left Ventricular Systolic and Diastolic Function

Cited by 56 publications

References 0 publications

Does the β-Blocker Nebivolol Increase Coronary Flow Reserve?

Does the β-Blocker Nebivolol Increase Coronary Flow Reserve?

Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial

The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension

Contact Info

Product

Resources

About